Glenmark Pharmaceuticals: US launches and cash generation remain key triggers; upgrade to ADD from REDUCE |
| Stock turns attractive on a relative basis |
| US generics - dermatology launches hold the key |
| US Dollar-denominated debt appears manageable |
|
Sector alerts |
Automobiles: Sluggish sales signify weak start to the festive season |
| Hero Motocorp performs better than peers |
| Maruti Suzuki volumes in line with estimates |
| M&M UV volumes continue to post steep decline |
| Tata Motors standalone business remains under pressure |
| Key themes to play in the sector |
|
Industrials: Land acquisition bill - clarity in process; industry to fend for itself |
| Key highlights - markedly different form old law in terms of scope, consent, price, rehabilitation |
| Parliamentary standing committee (broader political opinion) had stricter suggestions |
| State Governments have a strong leeway in setting price, thresholds for R&R in private acquisition |
| Defined process is a positive; industry has to fend for itself |
|
No comments:
Post a Comment